Hendrikus Hessel Boersma

PhD,Department of Hospital Pharmacist/ Clinical Pharmacologist,

University Medical Center Groningen

Netherlands.

Hendrikus Boersma was born in 1968 in Leeuwarden, the Netherlands. In 1996, he graduated as a pharmacist at Groningen University. From 1998-2000, Hendrikus Boersma was a resident in Clinical Pharmacy and performed research, leading to the PhD-thesis entitled “Annexin A5: pharmacology, radiopharmaceutical aspects and cell death imaging” at Maastricht University Hospital, in 2006. In 2000, he became a Clinical Pharmacist. Moreover, he was certified as a clinical pharmacologist in 2003. In 2007, he moved to the UMCG in Groningen. His major fields of interest are: radiopharmacy (QA/QP/GMP-tasks), and cardiovascular imaging research. Furthermore, he is a member of the Institutional Review Board. He was appointed as assistant professor in 2013, and in 2014, he became principal investigator. He contributed as an author to over 50 scientific publications (citations (ISI-web): > 1000, h-index = 14). Being a Qualified Person, he is strongly involved in the maintenance of the GMP system within the section of Radiochemistry/ Radiopharmacy, and facilitates GMP-implementation of radiopharmaceutical compounds as well as performance of contract research. Moreover, he releases radiopharmaceuticals which are shipped to other hospitals and is involved in the radiopharmaceutical commercialization project of the Nuclear Medicine and Molecular Imaging department at the UMCG. Within his research activities, he focusses on multidisciplinairy co-operation and creating as well as facilitating international networks. The latter led to several international master student exchanges and two PhD-student-positions with strong international connections. Furthermore, his connections may lead to the organization and conduction of clinical trials in the near future. Moreover, he is a member of the Ethics review board at the UMCG. Within the coming years, when Nuclear medicine and Radiology are integrated towards a truly imaging profession, he intends to become an imaging pharmacist, with additional attention towards development and facilitation of e.g. GMP-production and release of MRI and fluorescent imaging agents for human use.

Interdisciplinary, translational cardiovascular research; Atherosclerosis imaging; Imaging of cell death.